Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A

Trial Profile

An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efmoroctocog alfa (Primary) ; Factor VIII stimulants
  • Indications Haemophilia A
  • Focus Registrational; Therapeutic Use
  • Acronyms Kids A-LONG; Kids ALONG
  • Sponsors Biogen; Bioverativ
  • Most Recent Events

    • 14 Mar 2021 Results of population pharmacokinetic model from NCT01027377, NCT01181128 and NCT01458106 published in the Journal of Clinical Pharmacology
    • 10 May 2019 According to a Swedish Orphan Biovitrum media release, final pooled post-hoc analysis data from A-LONG, Kids A-LONG and ASPIRE studies will be presented at the World Federation of Hemophilia's 16th International Musculoskeletal Congress (MSK).
    • 24 Apr 2019 According to a Swedish Orphan Biovitrum media release, long term safety and efficay data was presented at the European Association of Haemophilia and Allied Disorders (EAHAD) conference.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top